Samsung Biologics Co Ltd Total Assets
Samsung Biologics Co Ltd total assets. Based on the latest financial reports, Samsung Biologics Co Ltd (207940) holds total assets worth ₩12.65 Trillion KRW (≈ $8.57 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Samsung Biologics Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Samsung Biologics Co Ltd (2014–2025)
Total assets of Samsung Biologics Co Ltd from 2014 to 2025. This chart illustrates how Samsung Biologics Co Ltd's total assets have evolved over time, based on quarterly financial data. See Samsung Biologics Co Ltd (207940) share price today for real-time trading data and today's change.
Samsung Biologics Co Ltd - Asset Composition Analysis
Samsung Biologics Co Ltd Total Assets Breakdown (December 2025)
Samsung Biologics Co Ltd total assets breakdown as of December 2025. Samsung Biologics Co Ltd's total assets of ₩12.65 Trillion consist of 39.9% current assets and 60.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.4% |
| Accounts Receivable | ₩654.73 Billion | 5.9% |
| Inventory | ₩2.13 Trillion | 19.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩60.19 Billion | 0.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Samsung Biologics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 207940 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samsung Biologics Co Ltd's current assets represent 39.9% of total assets in 2025, an increase from 16.0% in 2014.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 7.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
Samsung Biologics Co Ltd Competitors by Total Assets
Key competitors of Samsung Biologics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Samsung Biologics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.80 | 1.57 | 2.94 |
| Quick Ratio | 1.01 | 0.72 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩2.36 Trillion | ₩2.06 Trillion | ₩1.72 Trillion |
Samsung Biologics Co Ltd - Advanced Valuation Insights
This section examines the relationship between Samsung Biologics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.97 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -36.2% |
| Total Assets | ₩11.06 Trillion |
| Market Capitalization | $46.65 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Samsung Biologics Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Samsung Biologics Co Ltd's assets decreased by 36.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Samsung Biologics Co Ltd (2014–2025)
The table below shows the annual total assets of Samsung Biologics Co Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩11.06 Trillion ≈ $7.50 Billion |
-36.20% |
| 2024-12-31 | ₩17.34 Trillion ≈ $11.75 Billion |
+8.04% |
| 2023-12-31 | ₩16.05 Trillion ≈ $10.87 Billion |
-3.23% |
| 2022-12-31 | ₩16.58 Trillion ≈ $11.24 Billion |
+108.06% |
| 2021-12-31 | ₩7.97 Trillion ≈ $5.40 Billion |
+24.06% |
| 2020-12-31 | ₩6.42 Trillion ≈ $4.35 Billion |
+8.67% |
| 2019-12-31 | ₩5.91 Trillion ≈ $4.01 Billion |
-1.15% |
| 2018-12-31 | ₩5.98 Trillion ≈ $4.05 Billion |
-16.74% |
| 2017-12-31 | ₩7.18 Trillion ≈ $4.87 Billion |
-4.65% |
| 2016-12-31 | ₩7.53 Trillion ≈ $5.11 Billion |
+26.38% |
| 2015-12-31 | ₩5.96 Trillion ≈ $4.04 Billion |
+339.66% |
| 2014-12-31 | ₩1.36 Trillion ≈ $918.74 Million |
-- |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offe… Read more